Autonomic dysfunction and hemodynamic management after acute spinal cord injury: blood pressure targets, perfusion strategies, and emerging therapies

急性脊髓损伤后自主神经功能障碍和血流动力学管理:血压目标、灌注策略和新兴疗法

阅读:2

Abstract

OBJECTIVE: Acute spinal cord injury (SCI) produces profound cardiovascular instability that exacerbates secondary damage, emphasizing the need for timely blood pressure management and hemodynamic support. While stabilizing hemodynamics is central to acute SCI management, evidence guiding optimal mean arterial pressure (MAP) targets, vasopressor selection, and management strategies remains limited. We conducted a narrative, comprehensive review of peer-reviewed clinical and preclinical studies addressing hemodynamic management after SCI, defined here as the first 7 days after injury, including MAP augmentation, spinal cord perfusion pressure (SCPP) monitoring, vasopressor selection, and neuromodulatory approaches. RESULTS: Observational studies show that even transient hypotensive episodes within the first 72 h worsen neurological recovery. Updated guidelines recommend maintaining MAP between 75 to 80 and 90 to 95 mmHg for 3 to 7 days following injury. Norepinephrine is favored as first-line therapy because it reliably raises MAP with fewer adverse effects than other vasopressors. Neuromodulation with tSCS or eSCS has been shown to restore blood pressure and stabilize cardiovascular control in chronic SCI. Emerging evidence suggest these neuromodulatory approaches may be adapted for acute care. SCPP-guided strategies using lumbar cerebrospinal fluid drainage or direct intraspinal monitoring better reflect local perfusion and predict outcomes more accurately than MAP alone, although their use is limited to specialized centers. CONCLUSION: Hemodynamic management after SCI should be considered a therapeutic intervention that directly modifies secondary injury mechanisms. Refining MAP targets, expanding access to SCPP-guided care, and evaluating staged neuromodulation, could enhance precision and individualized care to improve long-term recovery. Large-scale multicenter trials will be essential to establish protocols that improve both neurological and cardiovascular outcomes after SCI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。